Statera BioPharma Gross Profit

Statera BioPharma (STAB) currently reports a gross profit of $2.6M as of September 2022. That compares with $120K in the prior-year period — up 2048.8% year over year. That is below the Healthcare sector average of $67B. Use the charts on this page to explore Statera BioPharma's gross profit history and peer comparisons.

Statera BioPharma's gross profit increased from $120K to $2.6M — a 2048.8% year-over-year increase (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Statera BioPharma's gross profit of $2.6M is lower than the Healthcare sector average of $67B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Statera BioPharma reported $2.6M in gross profit as of September 2022. That compares with $120K in the prior-year period — up 2048.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $2.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $67B. From there, open related valuation or income-statement pages for Statera BioPharma, and consider following STAB for alerts when major investors trade the stock.